Bristol-Myers Squibb Company
BIARYL KINASE INHIBITORS
Last updated:
Abstract:
The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
Status:
Application
Type:
Utility
Filling date:
5 Mar 2021
Issue date:
9 Sep 2021